Tiziana Life Sciences Ltd (TLSA) Stock Price, Quote & News

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: www.tizianalifesciences.com

Address:

14/15 Conduit Street, London, United Kingdom

rispi Apr. 4 at 10:46 AM

Easter recap: $IMMP is dead and can easily go down another 50%; $TLSA is an hidden gem with insiders at almost half OS, funded for at least one year and plenty of readout; $TANH they are crazy, it’s a gamble; We’re also bullish on NatGas Henry Hub and European gas TTF. Best wishes

0 · Reply

rispi Apr. 4 at 10:35 AM

$TLSA CEO has a pretty solid experience in biopharma and here he owns more than 40 mil shares.

0 · Reply

ThinkYouCan Apr. 3 at 7:55 PM

$SPY $DJT $TLSA $NVDA $BTC.X My biggest fear is Trump will want to launch nukes. If you think about it the ultimate power move is launching a nuke. His narcissim and ego could push him to that point. All he needs is a 'Trump excuse'.

1 · Reply

Huguenots Apr. 2 at 10:19 PM

$TLSA

0 · Reply

Huguenots Apr. 2 at 10:19 PM

$TLSA I guess this will go up at some point, I'm fairly optimistic - unless WW3 finishes civilisation

1 · Reply

naz2hi Apr. 2 at 5:15 PM

$USO $UCO $TLSA ... The latest: -- Trump threatens Iran (again): "make a deal before it's too late" - - $WTI drops on reports of Iran-Oman coordination to reopen strait. -- Iran issues Israel/Gulf logistics hubs target list; IRGC targets $AMZN Cloud computing center in Bahrain -- US intelligence assessments say Iran is not ready to negotiate given the belief that it has the strategic upper-hand, and doesn't believe Trump is 'serious' about talks: NYT

2 · Reply

naz2hi Apr. 2 at 10:15 AM

$USO $TLSA $DJT $SPY … Oh well, it now looks like🍊Dumbo's 𝗲𝗮𝘀𝘆-𝗽𝗲𝗮𝘀𝘆 𝟯-𝗱𝗮𝘆 𝘄𝗮𝗿 𝗶𝘀 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝘁𝗮𝗸𝗲 𝗮𝘀 𝗹𝗼𝗻𝗴 𝗮𝘀 𝘁𝗵𝗲 𝗔𝗳𝗴𝗵𝗮𝗻 𝗪𝗮𝗿. Good thing I got out of my sublease in 𝗕𝗼𝗼𝗺-𝗕𝗼𝗼𝗺 💣💣💣 𝗧𝗲𝗹 𝗔𝘃𝗶𝘃.

0 · Reply

rispi Apr. 2 at 6:00 AM

$TLSA https://www.sec.gov/Archives/edgar/data/1723069/000121390026037988/ea028453901ex99-1.htm

2 · Reply

naz2hi Apr. 2 at 1:58 AM

$USO $TLSA $DJT $SPY ... well there you go folks. Chump's Apr. Fools Day speech... And once again the joke is on us. https://m.youtube.com/watch?v=EGLJ2xNLeZc

0 · Reply

naz2hi Apr. 2 at 1:44 AM

$USO $TLSA $DJT $SPY ... I can't believe I actually listened to that incoherent babbling idiot. Even demented FJB made more sense than this moron at this point. What a lying pile of 💩 Trump is! He averaged around 18 lies per minute. And for those still wondering how the market will react to this garbage tomorrow... OIL just jumped up another +3.30% right now. So theres your answer on what the market thinks of this 🍊 🤡

0 · Reply

Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum

Apr 1, 2026, 7:00 AM EDT - 4 days ago

Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging

Feb 25, 2026, 7:00 AM EST - 5 weeks ago

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

Jan 20, 2026, 11:15 AM EST - 2 months ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 16, 2026, 2:45 PM EST - 2 months ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Jan 16, 2026, 7:00 AM EST - 2 months ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 9, 2026, 7:00 AM EST - 3 months ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

Dec 29, 2025, 8:00 AM EST - 3 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Dec 19, 2025, 11:00 AM EST - 3 months ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 17, 2025, 10:00 AM EST - 3 months ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Dec 17, 2025, 8:45 AM EST - 3 months ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

Dec 15, 2025, 3:07 PM EST - 3 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dec 15, 2025, 7:30 AM EST - 3 months ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Dec 12, 2025, 2:10 PM EST - 4 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

Dec 2, 2025, 7:00 AM EST - 4 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Nov 25, 2025, 8:30 AM EST - 4 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 13, 2025, 8:30 AM EST - 5 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Oct 31, 2025, 9:43 AM EDT - 5 months ago

Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot

Oct 29, 2025, 7:00 AM EDT - 5 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Sep 30, 2025, 8:30 AM EDT - 6 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 24, 2025, 8:30 AM EDT - 6 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 15, 2025, 8:00 AM EDT - 7 months ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 5, 2025, 8:30 AM EDT - 7 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Aug 14, 2025, 8:30 AM EDT - 8 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 8 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Jul 21, 2025, 7:00 AM EDT - 9 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jun 13, 2025, 11:08 PM EDT - 10 months ago

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Jun 13, 2025, 10:30 AM EDT - 10 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 8:30 AM EDT - 10 months ago

Tiziana Life Sciences to Present at the Bio International Convention

May 23, 2025, 7:00 AM EDT - 11 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 11 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 9, 2025, 7:00 AM EDT - 11 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 6, 2025, 7:00 AM EDT - 11 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 11, 2025, 9:15 AM EST - 1 year ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Jan 23, 2025, 3:00 PM EST - 1 year ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 8:54 AM EST - 1 year ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 22, 2025, 4:05 PM EST - 1 year ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 8, 2025, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Nov 1, 2024, 1:00 PM EDT - 1 year ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Oct 30, 2024, 10:29 PM EDT - 1 year ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

rispi Apr. 4 at 10:46 AM

0 · Reply

rispi Apr. 4 at 10:35 AM

$TLSA CEO has a pretty solid experience in biopharma and here he owns more than 40 mil shares.

0 · Reply

ThinkYouCan Apr. 3 at 7:55 PM

1 · Reply

Huguenots Apr. 2 at 10:19 PM

$TLSA

0 · Reply

Huguenots Apr. 2 at 10:19 PM

$TLSA I guess this will go up at some point, I'm fairly optimistic - unless WW3 finishes civilisation

1 · Reply

naz2hi Apr. 2 at 5:15 PM

2 · Reply

naz2hi Apr. 2 at 10:15 AM

0 · Reply

rispi Apr. 2 at 6:00 AM

$TLSA https://www.sec.gov/Archives/edgar/data/1723069/000121390026037988/ea028453901ex99-1.htm

2 · Reply

naz2hi Apr. 2 at 1:58 AM

$USO $TLSA $DJT $SPY ... well there you go folks. Chump's Apr. Fools Day speech... And once again the joke is on us. https://m.youtube.com/watch?v=EGLJ2xNLeZc

0 · Reply

naz2hi Apr. 2 at 1:44 AM

0 · Reply

naz2hi Apr. 1 at 10:48 PM

$USO $DJT $ORCL $TLSA ... Trump better invest in a orange Trumpsuit, bc given the direction of the GOP's poll numbers lately. 📉 If they loses the Senate too in November, it will probably mean impeachment, trial and some ...

0 · Reply

rispi Apr. 1 at 7:42 PM

$TLSA When insiders are at almost half % of outstanding and still buying, for me is a big big green flag

0 · Reply

RichP0 Apr. 1 at 6:14 PM

$TLSA I love how many different indications Foralumab is in. Not a one trick pony!!

0 · Reply

prismmarketview Apr. 1 at 5:11 PM

$TLSA TizianaLS Reports Promising Data Showing Nasal Anti-CD3 May Improve Age-Related Cognitive Decline https://prismmarketview.com/tiziana-reports-promising-data-showing-nasal-anti-cd3-may-improve-age-related-cognitive-decline/

0 · Reply

Housatonic1864 Apr. 1 at 3:03 PM

$TLSA pay close attention, good news followed by good news🫡 Wait for it🫡

0 · Reply

rispi Apr. 1 at 1:17 PM

$TLSA Ohhhh buddy!!!

0 · Reply

rispi Apr. 1 at 12:55 PM

$TLSA “These preclinical results are highly encouraging and build on our growing body of evidence that nasal foralumab modulates the immune system to reduce neuroinflammation,” said Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital. “By targeting T cells to influence microglial behavior and promote brain repair mechanisms like neurogenesis, nasal anti-CD3 offers a differentiated, non-invasive approach with potential applications in age related cognitive impairment.”

0 · Reply

rispi Apr. 1 at 12:52 PM

$TLSA https://finviz.com/news/341608/tiziana-announces-data-showing-nasal-anti-cd3-improves-cognition-associated-with-aging

0 · Reply

rispi Apr. 1 at 12:03 PM

$TLSA Good news for everyone

0 · Reply

G101SPM Apr. 1 at 11:40 AM

$TLSA $1.17 bid Holding long position UPDATE: Tiziana Life Sciences announces positive preclinical data highlighting nasal anti-CD3’s potential as a novel approach to address neuroinflammation associated with aging, which contributes to cognitive decline in age-related disorders. Note: n the study, nasal anti-CD3 reversed key aspects of brain aging, and improved cognition. Key study findings: Nasal anti-CD3 dampens microglial activation that drives chronic neuroinflammation. This reduction in inflammation, which is strongly linked to cognitive decline, suggests the therapy could help mitigate the inflammatory burden and slow aspects of the aging process. Nasal anti-CD3 enhances neurogenesis in the hippocampus, a region critical for learning and memory and reduces cellular senescence by down regulating inflammatory markers and age-related genes.

0 · Reply

rp6577 Apr. 1 at 11:25 AM

$TLSA just more and more evidence showing how Foralumab is going to be a blockbuster $XBI

0 · Reply

Chellybaby Apr. 1 at 11:03 AM

$TLSA https://www.tizianalifesciences.com/tiziana-announces-data-showing-nasal-anti-cd3-improves-cognition-associated-with-aging/

0 · Reply

Market Cap	159.07M
Revenue (ttm)	0.00
Net Income (ttm)	-11.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	111,100
Avg Vol	156,066
Day's Range	N/A - N/A
Shares Out	127.26M
Stochastic %K	30%
Beta	0.35
Analysts	Strong Sell
Price Target	$8.00